Rezafungin Versus Caspofungin in a Phase 2, Randomized, Double-blind Study for the Treatment of Candidemia and Invasive Candidiasis: The STRIVE Trial
George R Thompson, Alex Soriano, Athanasios Skoutelis, Jose A Vazquez, Patrick M Honore, Juan P Horcajada, Herbert Spapen, Matteo Bassetti, Luis Ostrosky-Zeichner, Anita F Das, Rolando M Viani, Taylor Sandison, Peter G Pappas, George R Thompson, Alex Soriano, Athanasios Skoutelis, Jose A Vazquez, Patrick M Honore, Juan P Horcajada, Herbert Spapen, Matteo Bassetti, Luis Ostrosky-Zeichner, Anita F Das, Rolando M Viani, Taylor Sandison, Peter G Pappas
Abstract
Background: Rezafungin (RZF) is a novel echinocandin exhibiting distinctive pharmacokinetics/pharmacodynamics. STRIVE was a phase 2, double-blind, randomized trial designed to compare the safety and efficacy of RZF once weekly (QWk) to caspofungin (CAS) once daily for treatment of candidemia and/or invasive candidiasis (IC).
Methods: Adults with systemic signs and mycological confirmation of candidemia and/or IC were randomized to RZF 400 mg QWk (400 mg), RZF 400 mg on week 1 then 200 mg QWk (400/200 mg), or CAS 70 mg as a loading dose followed by 50 mg daily for ≤4 weeks. Efficacy assessments included overall cure (resolution of signs of candidemia/IC + mycological eradication) at day 14 (primary endpoint), investigator-assessed clinical response at day 14, and 30-day all-cause mortality (ACM) (secondary endpoints), and time to negative blood culture. Safety was evaluated by adverse events and ACM through follow-up.
Results: Of 207 patients enrolled, 183 were in the microbiological intent-to-treat population (~21% IC). Overall cure rates were 60.5% (46/76) for RZF 400 mg, 76.1% (35/46) for RZF 400/200 mg, and 67.2% (41/61) for CAS; investigator-assessed clinical cure rates were 69.7% (53/76), 80.4% (37/46), and 70.5% (43/61), respectively. In total, 30-day ACM was 15.8% for RZF 400 mg, 4.4% for RZF 400/200 mg, and 13.1% for CAS. Candidemia was cleared in 19.5 and 22.8 hours in RZF and CAS patients, respectively. No concerning safety trends were observed; ACM through follow-up was 15.2% (21/138) for RZF and 18.8% (13/69) for CAS.
Conclusions: RZF was safe and efficacious in the treatment of candidemia and/or IC.
Clinical trials registration: NCT02734862.
Keywords: candidemia; echinocandins; rezafungin; systemic antifungal therapy.
© The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America.
Figures
References
- Pappas PG, Kauffman CA, Andes DR, et al. . Clinical practice guideline for the management of candidiasis: 2016 update by the Infectious Diseases Society of America. Clin Infect Dis 2016; 62:e1–50.
- Andes DR, Safdar N, Baddley JW, et al. ; Mycoses Study Group . Impact of treatment strategy on outcomes in patients with candidemia and other forms of invasive candidiasis: a patient-level quantitative review of randomized trials. Clin Infect Dis 2012; 54:1110–22.
- Kullberg BJ, Viscoli C, Pappas PG, et al. . Isavuconazole versus caspofungin in the treatment of candidemia and other invasive Candida infections: the ACTIVE trial. Clin Infect Dis 2019; 68:1981–9.
- Cornely OA, Bassetti M, Calandra T, et al. ; ESCMID Fungal Infection Study Group . ESCMID* guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients. Clin Microbiol Infect 2012; 18(Suppl 7):19–37.
- Zhao Y, Prideaux B, Nagasaki Y, et al. . Unraveling drug penetration of echinocandin antifungals at the site of infection in an intra-abdominal abscess model. Antimicrob Agents Chemother 2017; 61. doi: 10.1128/AAC.01009-17.
- Grau S, Luque S, Campillo N, et al. . Plasma and peritoneal fluid population pharmacokinetics of micafungin in post-surgical patients with severe peritonitis. J Antimicrob Chemother 2015; 70:2854–61.
- Howard SJ, Livermore J, Sharp A, et al. . Pharmacodynamics of echinocandins against Candida glabrata: requirement for dosage escalation to achieve maximal antifungal activity in neutropenic hosts. Antimicrob Agents Chemother 2011; 55:4880–7.
- Bader JC, Bhavnani SM, Andes DR, Ambrose PG. We can do better: a fresh look at echinocandin dosing. J Antimicrob Chemother 2018; 73(suppl_1):i44–50.
- Lakota EA, Bader JC, Ong V, et al. . Pharmacological basis of CD101 efficacy: exposure shape matters. Antimicrob Agents Chemother 2017; 61.
- Shields RK, Nguyen MH, Press EG, Clancy CJ. Abdominal candidiasis is a hidden reservoir of echinocandin resistance. Antimicrob Agents Chemother 2014; 12:7601–5.
- Sandison T, Ong V, Lee J, Thye D. Safety and pharmacokinetics of CD101 IV, a novel echinocandin, in healthy adults. Antimicrob Agents Chemother 2017; 61.
- Lepak AJ, Zhao M, VanScoy B, Ambrose PG, Andes DR. Pharmacodynamics of a long-acting echinocandin, CD101, in a neutropenic invasive-candidiasis murine model using an extended-interval dosing design. Antimicrob Agents Chemother 2018; 11:e01572–18.
- Hager CL, Larkin EL, Long LA, Ghannoum MA. Evaluation of the efficacy of rezafungin, a novel echinocandin, in the treatment of disseminated Candida auris infection using an immunocompromised mouse model. J Antimicrob Chemother 2018; 8:2085–8.
- Lepak AJ, Zhao M, Andes DR. Determination of pharmacodynamic target exposures for rezafungin against Candida tropicalis and Candida dubliniensis in the neutropenic mouse disseminated candidiasis model. Antimicrob Agents Chemother 2019; 63.
- Miesel L, Lin KY, Ong V. Rezafungin treatment in mouse models of invasive candidiasis and aspergillosis: insights on the PK/PD pharmacometrics of rezafungin efficacy. Pharmacol Res Perspect 2019; 6:e00546.
- Flanagan S, Goodman DB, Jandourek A, O’Reilly T, Sandison T. Lack of effect of rezafungin on QT/QTc interval in healthy subjects. Clin Pharmacol Drug Dev 2020; 9:456–65.
- Pappas PG, Rotstein CM, Betts RF, et al. . Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis. Clin Infect Dis 2007; 45:883–93.
- Wiederhold NP. Paradoxical echinocandin activity: a limited in vitro phenomenon? Med Mycol 2009; 47(Suppl 1):S369–75.
- Gangneux JP, Lortholary O, Cornely OA, Pagano L. 9th trends in medical mycology held on 11–14 October 2019, Nice, France, organized under the auspices of EORTC-IDG and ECMM. J Fungi (Basel) 2019; 5.
- Safdar A, Rodriguez G, Rolston KV, et al. . High-dose caspofungin combination antifungal therapy in patients with hematologic malignancies and hematopoietic stem cell transplantation. Bone Marrow Transplant 2007; 3:157–64.
- Safdar A, Rodriguez G, Zuniga J, Al Akhrass F, Pande A. High-dose caspofungin as a component of combination antifungal therapy in 91 patients with neoplastic diseases and hematopoietic stem cell transplantation: a critical review of short-term and long-term adverse events. J Pharm Pract 2015; 28:175–82.
- Betts RF, Nucci M, Talwar D, et al. . A Multicenter, double-blind trial of a high-dose caspofungin treatment regimen versus a standard caspofungin treatment regimen for adult patients with invasive candidiasis. Clin Infect Dis 2009; 48:1676–84.
- Yamazaki S, Nakamura F, Yoshimi A, Ichikawa M, Nannya Y, Kurokawa M. Safety of high-dose micafungin for patients with hematological diseases. Leuk Lymphoma 2014; 55:2572–6.
- Reboli AC, Rotstein C, Pappas PG, et al. ; Anidulafungin Study Group . Anidulafungin versus fluconazole for invasive candidiasis. N Engl J Med 2007; 356:2472–82.
- Jullien V, Azoulay E, Schwebel C, et al. ; EMPIRICUS Trial Study Group . Population pharmacokinetics of micafungin in ICU patients with sepsis and mechanical ventilation. J Antimicrob Chemother 2017; 72:181–9.
- Petraitiene R, Petraitis V, Hope WW, Walsh TJ. Intermittent dosing of micafungin is effective for treatment of experimental disseminated candidiasis in persistently neutropenic rabbits. Clin Infect Dis 2015; 61(Suppl 6):S643–51.
- Zhao Y, Perez WB, Jimenez-Ortigosa C, et al. . CD101: a novel long-acting echinocandin. Cell Microbiol 2016; 18:1308–16.
- Maseda E, Grau S, Luque S, et al. . Population pharmacokinetics/pharmacodynamics of micafungin against Candida species in obese, critically ill, and morbidly obese critically ill patients. Crit Care 2018; 22:94.
- Wasmann RE, Ter Heine R, van Dongen EP, et al. . Pharmacokinetics of anidulafungin in obese and normal-weight adults. Antimicrob Agents Chemother 2018; 62. doi: 10.1128/AAC.00063-18.
Source: PubMed